NCT02492737已完成1 期
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 主要终点
- Safety/tolerability; incidence of adverse events
研究概览
简要总结
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
详细描述
The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-881 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs or the patient is removed at the discretion of the investigator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 years of age
- •Patients must have documented IDH1 and/or IDH2 gene-mutated disease
- •Patients must have an advanced hematologic malignancy with an IDH1 and/or IDH2 mutation
- •Patient must be able to understand and willing to sign an informed consent
- •Patients must have ECOG PS of 0 to 2
- •Patients must have adequate hepatic function as evidenced by serum total bilirubin ≤1.5 upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic involvement
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to involvement by the neoplasm under consideration for treatment
- •Patients must have adequate renal function as evidenced by a serum creatinine ≤2.0 × ULN or Creatinine clearance 40 mL/min based on the Cockroft-Gault glomerular filtration rate (GFR) estimation
- •Patients must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer
- •Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy. Patients with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
排除标准
- •Patients who have undergone HSCT within 60 days
- •Patients who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration
- •Patients who received an investigational agent <14 days prior
- •Patients who are pregnant or breast feeding
- •Patients with an active severe infection who require anti-infective therapy or with an unexplained fever >38.5°C during Screening visits or on their first day of study drug administration (at the discretion of the Investigator, patients with tumor fever may be enrolled)
- •Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1
- •Patients with a history of myocardial infarction within the last 6 months
- •Patients with known unstable or uncontrolled angina pectoris
- •Patients with a known history of severe and/or uncontrolled ventricular arrhythmias
- •Patients with QTc interval ≥450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events
- •Patients taking medications that are known to prolong the QT interval
- •Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
- •Patients with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during Screening
- •Patients with immediately life-threatening, severe complications of hematologic malignancies such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
研究组 & 干预措施
AG881
Experimental
AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
干预措施: AG881 (Drug)
结局指标
主要结局
Safety/tolerability; incidence of adverse events
时间窗: Up to 26 weeks, on average
Maximum Tolerated Dose and/or the recommended Phase II dose of AG-881 in patients with advanced hematologic malignancies
时间窗: Up to 26 weeks, on average
次要结局
- Clinical Activity according to the 2003 revised IWG criteria for AML, the 2006 modified IWG criteria for MDS, disease-specific response criteria for other hematologic malignancies(Up to 26 weeks, on average)
- Pharmacodynamic levels of AG-881(Up to 26 weeks, on average)
- Pharmacodynamic levels of 2-HG(Up to 26 weeks, on average)
- Pharmacokinetics of AG-881 in patients with advanced hematologic malignancies(Up to 26 weeks, on average)
研究者
相似试验
招募中
1 期
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic MalignanciesMyelodysplastic SyndromesNCT02074839Institut de Recherches Internationales Servier291
已完成
1 期
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 MutationChondrosarcomaOther Advanced Solid TumorsGliomaCholangiocarcinomaNCT02073994Institut de Recherches Internationales Servier174
已完成
1 期
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsAdvanced Solid Tumors CancerNCT03071757AbbVie139
已完成
1 期
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver InvolvementSolid TumorsNCT00882180Alnylam Pharmaceuticals41
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerAdvanced Prostate CancerMetastatic Prostate CancerNCT05800665Genentech, Inc.210